Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EF-009 in Pancreatic Cancer
NCT04381130Phase 2Not yet recruiting
- Sponsor
- Everfront Biotech Inc.
- Start
- Apr 2027
- Primary completion
- Dec 2029
- Modality
- Small Molecules, Device-based Delivery
01
Overview
Phase 2, open-label, single-arm trial of EF-009 in pancreatic cancer (PC), sponsored by Everfront Biotech Inc. Primary endpoints: Maximum Tolerated Dose at 21 days and Overall survival at 2 years. Planned start Apr 2027; status: not yet recruiting.
02
Drugs
EF-009
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04381130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04381130.